Aplagon, a clinical stage biopharmaceutical company dedicated to the development of first-in-class therapeutics for thrombo-inflammatory diseases, has announced the closing of a €7m financing round for the initiation of phase 2a of its clinical trials.

Swedish biopharmaceutical company AnaCardio has announced the completion of a Series A extension financing round that has raised $19m for its novel contractile agents. The round was co-led by Novo Holdings, Pureos Bioventures and Sound Bioventures.

Beckley Psytech Ltd, a clinical-stage biopharmaceutical company that specialises in the production of accessible medicines for mental health conditions, has announced positive results for the phase 2a study into BPL-003 in patients with moderate-to-severe alcohol use disorder (AUD).

Novadip Biosciences, a clinical stage biotechnology company with a specialty in regenerative medicine, has announced the results of its 12-month post-surgical visit as part of phase 1b/2a of the NCT05693558 trial.

French biotech AdipoPharma has announced that it has secured funding for a clinical trial into its type 2 diabetes therapeutic, PATAS.

Global biopharma company GSK has announced positive phase 3 results for its cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) treatment, linerixibat, which is currently being studied in the GLISTEN trial.

Puma Biotechnology has announced the initiation of its alisertib in cancer (ALISCATM-Breast1) phase 2 trial of alisertib in combination with endocrine therapy. Based on the outcomes of the trial, the company anticipates to meet with the US Food and Drug Administration (FDA) regarding an approval pathway.

UK-based Barinthus Biotherapeutics has announced data from its ongoing phase 2b HBV003 clinical trial, which was presented at the American Association for the Study of Liver Diseases (AASLD) Meeting 2024.

Clinical-stage biotech company Aravax has announced that it has completed phase 2 recruitment for its precision therapy (pvx108) study, which investigates treatment of peanut allergies.

Chiesi Global Rare Diseases has announced the results from its BRIGHT trial, which evaluates the efficacy of enzyme-replacement therapy drug elfabrio at twice the approved dose in patients who have been treated with agalsidase alfa or beta. The current approved dose of pegunigalside alfa-iwxj (elfabrio) is 1 milligram (mg) per kilogram (kg) administered every two weeks.

Sobi and Apellis Pharmaceuticals have announced the results from the VALIANT trial, which highlight that systemic pegcetacoplan treatment could benefit patients with c3 glomerulopathy (c3g) and primary immune complex membranoproliferative glomerulonephritis (ic-mpgn).

Clinical-stage biotech company Rallybio corporation has announced that it has received approval from two regulatory bodies for its clinical trial applications (CTAS) for a phase 2 study involving pregnant women.